Xenon Pharmaceuticals Inc. (XENE) stock
Close on Nov 11, 2026Market cap $4.08BP/E –Yield –
Xenon Pharmaceuticals Inc. saw revenue fall 100.0% to $0 over the twelve months to Sep 30, 2026. Free cash flow was -$357.11M. At the latest close the market valued the company at $4.08B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.08B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.56
- Dividend yield
- –
- Free cash flow yield
- -8.76%
Fundamentals
- Revenue
- $0
- Net income
- -$428.73M
- EPS, diluted
- -$4.70
- Free cash flow
- -$357.11M
- Book value per share
- $11.49
- Diluted shares
- 100M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $41.39
- Open
- $41.46
- Day's range
- $40.88 – $42.17
- Volume
- 1,253,743
- Average volume (20 days)
- 1,337,216
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 0.63
- 52-week range
- $33.38 – $72.66
- RSI (14 days)
- 62.7
- Volatility (1 year)
- 68.0%
- Relative volume
- 0.87×
- WACC
- 8.0%
On 1 of our idea list: Insiders buying the dip
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | XENE | S&P 500 | Difference | XENE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.5% | -2.4% | +17.9 pts | ||
| 3 months | -33.4% | -1.2% | −32.3 pts | ||
| Year to date | -6.1% | +12.3% | −18.4 pts | ||
| 1 year | +5.5% | +12.4% | −7.0 pts | ||
| 3 years | +46.0% | +78.8% | −32.8 pts | +13.5% | +21.4% |
| 5 years | +32.8% | +75.2% | −42.3 pts | +5.8% | +11.9% |
| 10 years | +439.7% | +311.1% | +128.6 pts | +18.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Xenon Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Update
- Update
About Xenon Pharmaceuticals
Pharmaceutical Preparations
The biopharmaceutical company specializes in discovering, clinically developing, and commercializing therapeutics aimed at treating neurological and psychiatric conditions. Its primary focus is on advancing ion channel modulators, featuring its lead investigational candidate, azetukalner, a Kv7 potassium channel opener evaluated in late-stage clinical trials for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. Additional early-stage programs target sodium and potassium channels for indications including pain and Dravet syndrome, alongside partnered research initiatives for epilepsy. The organization designs its therapies for patients suffering from difficult-to-manage central nervous system disorders.
Company profile, executives and historyXenon Pharmaceuticals stock: common questions
What is Xenon Pharmaceuticals's stock price?
XENE closed at $42.10 on Nov 11, 2026, up 1.72% on the day. Over the past 52 weeks it traded between $33.38 and $72.66.
What is Xenon Pharmaceuticals's market cap?
Xenon Pharmaceuticals was worth $4.08B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is XENE's P/E ratio?
Xenon Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.70), so it has no meaningful P/E ratio.
How much revenue does Xenon Pharmaceuticals make?
Xenon Pharmaceuticals reported revenue of $0 for the twelve months to Sep 30, 2026, down 100.0% from a year earlier.
Does Xenon Pharmaceuticals pay a dividend?
No. Xenon Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Xenon Pharmaceuticals report earnings next?
Xenon Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has XENE stock performed over the past year?
Including dividends, XENE returned +5.5% over the past year, against +12.4% for the S&P 500.
How many XENE shares are sold short?
7M shares were sold short at the latest FINRA report, 7.62% of the float, or 6.4 days of average trading volume.
Who are Xenon Pharmaceuticals's competitors?
Companies most similar to Xenon Pharmaceuticals by business, industry and size include PRAX, NAMS, CAMP, ROIV, ZBIO.
See a number that looks wrong?